Sanofi India Limited is a pharmaceutical company in the healthcare sector, operating at meaningful scale with market cap ₹7,458.67 Cr. The company demonstrates strong financial positioning with ROE of 44.07%, zero debt, operating margins ranging 21–32%, and consistent dividend payouts reflecting robust cash generation.
Face value
₹10
Market cap
₹6,986 Cr
P/E
16.9×
P/B
8.1×
Dividend yield
7.9%
ROE
44.1%
ROCE
48.1%
Debt / equity
0
OPM
24.4%
EPS (TTM)
₹179.7
Book value
₹374.2
52-week high
₹4,807.1
52-week low
Key insights
Company research notes and source-linked reviews
Key risks
Share price declined 37.39% over 1 year and trades near 52w low (₹3,097); verify if driven by company-specific issues, sector headwinds, or valuation reset
Operating margin volatility of 10.5 percentage points (21.51–32.08% range) indicates vulnerability to cost, pricing, or product mix shifts
Quarterly revenue range of ₹406–536 Cr represents ~30% variation; assess whether customer/product concentration or demand volatility drive this
Promoter holding of 60.4% against public float of 14.04% may constrain liquidity; verify trading volume adequacy
Generated analysis · source review pending
Growth drivers
OPM improvement from 21.51% (Dec 2025) to 26.34% (Jun 2026) could accelerate net profit if margin level sustains
High ROE of 44.07% and zero debt enable reinvestment of earnings for compounding growth
Quarterly net profits of ₹61.7–102.6 Cr provide capital for organic investments or strategic moves
Verify whether revenue can accelerate beyond recent ₹406–536 Cr range through new product launches or market expansion
Generated analysis · source review pending
₹3,037.4-36%1Y
Beta
0.84
Moves with the index
Volatility (1y)
18.9%
Annualised, daily returns
RSI (14)
40.3
Neither overbought nor oversold
Rel. strength (1y)
-46.5%
Behind the market
Beta is measured against NIFTY 50 over three years of weekly returns — 1 moves with the index, above 1 amplifies it, below 1 damps it.
Quick read
rule-based
Pros
+Strong return on equity of 51.7% (3-yr avg)
+High return on capital employed of 63.1%
+Healthy operating margin of 24.4%
+Almost debt-free (debt/equity 0)
+Comfortable interest coverage of 313.7×
+Dividend yield of 7.9%
+High promoter holding of 60.4% with no pledge
Cons
−Trading at 8.1× book value
Research score
Structured signal from quality, growth, valuation and momentum.
40/100
Business quality
93
Growth
Revenue & net profit
₹ crore, by fiscal year
RevenuePAT
Margins
% of revenue, by fiscal year
OPMPAT margin
Peers
Comparable companies from the narrowest available industry classification.
Loading peers…
Financials
Reported profit and loss, balance sheet, cash flow and growth history.
Loading financials…
Ratios
Annual operating, return, leverage and working-capital ratios.
Loading ratios…
Shareholding
Quarterly ownership, named holders, insider transactions and disclosed deals.
Loading shareholding…
F&O
Current futures and options contracts with compact option-chain pages.
Loading f&o…
Fund holders
Mutual-fund schemes that disclosed a holding in the company.
Loading fund holders…
Documents
Annual reports, exchange filings, offer documents, ratings and earnings-call material.
Loading documents…
Events
Upcoming dates and the company’s corporate-action history.
Loading events…
Announcements
Latest exchange announcements, filings and downloadable documents.
Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.
Not in the F&O segment
Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.
Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Receipt Of Show Cause Notice From GST Authorities
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Receipt Of Show Cause Notice From GST Authorities